Orphan Drugs Summit 2015

Building a Collaborative Community

REGISTER NOW
WHEN 17-18 September 2015
WHERE Copenhagen, Denmark


New Features Explained!

A note from the editor

Changing times ask for solid relationships.

Times are changing. A renewed interest from big pharma in the rare disease landscape has awakened due to large-scale patent expirations, competition from generics & biosimilars, anemic pipelines, escalating clinical trial costs and a global health-care reform. This means that the traditional blockbuster model has become less viable while the revenue-generating potential of orphan drugs has shown to be huge with a greater return on investment than non-orphan drugs. According to EvaluatePharma, the orphan drugs sales will grow at an annual rate of 11% and constitute 19% of the total share of prescription drugs by 2020, totalling 176 billion dollars.

The rare disease landscape is very complex due to the large amount of stakeholders involved. Despite their different interests they have one goal in common: getting an orphan drug approval that will help save or improve lives. But there are many challenges on the road to orphan drug designation:

Changing environments ask for a changing conference. With the help of the audience we have been able to map the complex orphan drugs ecosystem, resulting in a whole new concept at the Orphan Drugs Summit 2015. This conference is specifically designed to enable future stakeholder interactions, which is much needed. Each session brings together different groups of stakeholders on specifically selected topics to help them build relationships and reach their goals. With the right relations and the right discussions we can help shape the future of healthcare by collaboration.

Flip the pages to see your ecosystem map and what sessions are specially designed for you. Start building your solid relationships right here, right now!

Welcome to the 5th annual Orphan Drugs Summit.

Sincerely,

maaike









Maaike Gerritse

Editorial Content Director, Orphan Drugs Summit

Watch a summary of the Orphan Drugs Survey results

Download the Orphan Drugs Summit 2015 agenda

Orphan-Drugs-Summit-2015-1Download the Orphan Drugs Summit 2015 agenda as a PDF- file: Orphan Drugs Summit 2015.pdf

Download Orphan Drugs Ecosystem Mapping Survey Report 2015

Download the Orphan Drugs Ecosystem Mapping Report 2015 as a PDF file: Orphan Drugs Ecosystem Mapping Report 2015.pdfOrphan-Drugs-Ecosystem-Mapping-Report-2015-1

shark1

Thank You!

The 2014 event became the most successful to date

Thank you for making the 4th edition of the Orphan Drugs Summit the most productive edition to date. Over 100 participants from all stakeholder positions registered for the conference. Delegates engaged with one another and participated in 14 plenary sessions, 6 stream sessions, 6 round table discussions, and 1 interactive panel.

Whilst the key pillars for orphan drug development remained prominent issues, this year we saw a real focus on collaboration. As we move forward it is becoming more apparent that the future of orphan drug development is intertwined with collaborative development. But what format will collaboration take? Will it be an agency and developer structure? Or will we see more complex and holistic approaches, led by various stakeholders including patient organizations?

Whatever combination stakeholders decide to create in regards to collaboration, pricing, reimbursement, market access and clinical development will continue to play a tremendous role. As we move into 2015 we will still assess these pertinent issues and analyze how they impact the orphan drugs landscape.

We invite you to join us, collaborate, network, and learn at the 5th edition of the Orphan Drugs Summit. Orphan Drugs Summit 2015 – Building a collaborative community

orphangeopicture

What our attendees had to say:

"Progressive, thought provoking and innovative, with cooperative networking"
Hoss Dowlat - Pharmabio Consulting

"It was a fruitful stimulating meeting with lots of networking opportunities"
Brigitte Happ - Happ consulting

"Very interesting meeting with relevant topics. Good way of organizing the meeting with different types of sessions"
Suzanna Theut Stehr-Nielsen - PTC Therapeutics Inc

"Extremely well organized, open discussions and overall pleasant"
Sigurdur Johannesson - AHCFE

"Extremely beneficial both from a content as also from a networking perspective"
Thomas Ogorka - OrphanReach

"A great introduction to the rare disease space and regulatory environment in Europe"
Chris Gibson - U. Utah

"Wonderful experience, great attendees, intimate setting, solid content"
Scott Schliebner - PRA

"This conference was informative, and I met many new people in the area of Orphan Drugs"
Bill Lobb - MME

"The conference offered and good and diverse introduction to the challenges with Orphan Drug development"
Kjeld S. Larsen - Zealand Pharma A/S

"A congress that surpassed all of my expectations. I will definitely attend next year!"
Jonathan Morton - Oxford PharmaGenesis

"The meeting mirrors the growth of Orphan Drugs and provides tools for companies"
Anders Waas - TikoMed

"A very well run conference with an excellent mixture of talks and interactions.  A pleasure to attend."
Audrey Jamieson - QCTR Ltd

"Nice to talk on equal terms to such a big variety of people from the Industry."
Susanne Rodholm - Zymenex A/S

2014 Post Event Report

Download the Orphan Drugs Post Show Report as a PDF file: Orphan Drugs Post Show Report 2014.pdf

List of Partners


Become a Partner
Connect with us:
Event Countdown
0 Days 0 Hours 0 Minutes 0 Seconds

Register Now

Register your seat today!

 Academic/Government 1090 EUR (excluding tax) Pharma/Biotech 1890 EUR (excluding tax) Solution Provider 2495 EUR (excluding tax)

Your name:

Job title:

Email:

Where did you hear about conference?:

 Telemarketing E-mail Social media Colleague refferal Other (please specify)

Name of company/organization:

Name of company/organization:

What Industry do you represent:
 SME Biotech BioPharma Drug Developers Large MNC Pharma Regulators Patient Registeries Government Regulators Contract research organization (CRO) Asset Managers Clinical Trial Managemnet Clinical Data Management Pharmaceutical Consulting Other

Billingaddress:

VAT nr:

Country:

Telephone no.:

Website link:

Message/comments: